Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line

被引：0
作者：
Seiichi Okabe
Tetsuzo Tauchi
Yuko Tanaka
Kazuma Ohyashiki
机构：
[1] Tokyo Medical University,First Department of Internal Medicine
来源：
Journal of Hematology & Oncology | / 4卷
关键词：
Imatinib; Chronic Myeloid Leukemia; Dasatinib; Nilotinib; Chronic Myeloid Leukemia Patient;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Nilotinib is approved for treatment of newly diagnosed chronic myeloid leukemia (CML) and it is shown superiority over imatinib in first-line treatment for patients of CML. In this study, we established a nilotinib-resistant cell line, K562NR, and evaluated the resistance to nilotinib and efficacy of dasatinib. We found activation of Lyn plays a dominant role in survival of the nilotinib-resistant cell line. We found dasatinib induces the apoptosis of nilotinib-resistant cells and inhibits Lyn kinase activity. This novel nilotinib-resistant CML cell line may help to explore novel therapy for CML.
引用
收藏
相关论文
共 50 条
  • [1] First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
    Guoqing Wei
    Shamudheen Rafiyath
    Delong Liu
    Journal of Hematology & Oncology, 3
  • [2] Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia
    Hoyle, Martin
    Rogers, Gabriel
    Moxham, Tiffany
    Liu, Zulian
    Stein, Ken
    VALUE IN HEALTH, 2011, 14 (08) : 1057 - 1067
  • [3] An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia
    Muresan, Bogdan
    Mamolo, Carla
    Cappelleri, Joseph C.
    Leip, Eric
    Viqueira, Andrea
    Heeg, Bart
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (05) : 801 - 809
  • [4] Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice
    DeAngelo, Daniel J.
    Attar, Eyal C.
    LEUKEMIA & LYMPHOMA, 2010, 51 (03) : 363 - 375
  • [5] Efficacy of Bosutinib in Imatinib-Resistant vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study
    Smith, B. Douglas
    Rosti, Gianantonio
    Bruemmendorf, Tim
    Roboz, Gail
    Gambacorti-Passerini, Carlo
    Charbonnier, Aude
    Viqueira, Andrea
    Leip, Eric
    Giles, Frank
    Ernst, Thomas
    Castagnetti, Frank
    Hochhaus, Andreas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S240 - S240
  • [6] Nilotinib and Dasatinib in the First-Line Therapy for chronic myeloid Leukemia
    Pretscher, Dominik
    Wilhelm, Martin
    MEDIZINISCHE KLINIK, 2010, 105 (08) : 588 - 588
  • [7] Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib
    Quintas-Cardama, Alfonso
    Jabbour, Elias J.
    LEUKEMIA RESEARCH, 2013, 37 (05) : 487 - 495
  • [8] Second-line use of dasatinib and nilotinib in a real-world patient population with chronic phase chronic myeloid leukemia
    Toptas, Tayfur
    Demirtas, Derya
    Yanik, Ahmet Mert
    Candan, Ozlem
    Arikan, Fatma
    Salim, Secil
    Menguc, Meral
    Yilmaz, Asu Fergun
    Tuglular, Tulin
    Kaygusuz Atagunduz, Isik
    HEMATOLOGY, 2025, 30 (01)
  • [9] Cost-Utility Analysis of Dasatinib and Nilotinib in Patients With Chronic Myeloid Leukemia Refractory to First-Line Treatment With Imatinib in Thailand
    Kulpeng, Wantanee
    Sompitak, Sumalai
    Jootar, Saengsuree
    Chansung, Kanchana
    Teerawattananon, Yot
    CLINICAL THERAPEUTICS, 2014, 36 (04) : 534 - 543
  • [10] Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients
    Breccia, Massimo
    Baccarani, Michele
    Rosti, Gianantonio
    Cottone, Francesco
    Cannella, Laura
    Guilhot, Francois
    Vignetti, Marco
    Efficace, Fabio
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2017, 15
12345